With respect to its pathogenesis, we show that SEMA3A is upregulated under conditions of high palmitic acid concentrations in female and male human LSECs and in multiple mouse models for MASLD. This evidence concerns the gene SEMA3A and metabolic dysfunction-associated steatotic liver disease.